메뉴 건너뛰기




Volumn 22, Issue 4, 2016, Pages 249-255

Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure

Author keywords

chronic heart failure; galectin 3; Serial biomarkers; sST2

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALECTIN 3; HEMOGLOBIN; POTASSIUM; PROTEIN; SODIUM; SOLUBLE SUPPRESSION OF TUMORIGENICITY 2 PROTEIN; TROPONIN T; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; GALECTIN-3, HUMAN; IL1RL1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN;

EID: 84942055106     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2015.07.017     Document Type: Article
Times cited : (34)

References (29)
  • 1
    • 23744514591 scopus 로고    scopus 로고
    • Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice
    • 1 McMurray, J., Cohen-Solal, A., Dietz, R., Eichhorn, E., Erhardt, L., Hobbs, F.D., et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice. Eur J Heart Fail 7 (2005), 710–721.
    • (2005) Eur J Heart Fail , vol.7 , pp. 710-721
    • McMurray, J.1    Cohen-Solal, A.2    Dietz, R.3    Eichhorn, E.4    Erhardt, L.5    Hobbs, F.D.6
  • 2
    • 2442479695 scopus 로고    scopus 로고
    • Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure
    • 2 Bristow, M.R., Saxon, L.A., Boehmer, J., Krueger, S., Kass, D.A., De Marco, T., et al., Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 (2004), 2140–2150.
    • (2004) N Engl J Med , vol.350 , pp. 2140-2150
    • Bristow, M.R.1    Saxon, L.A.2    Boehmer, J.3    Krueger, S.4    Kass, D.A.5    De Marco, T.6
  • 3
    • 24944519319 scopus 로고    scopus 로고
    • Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure
    • 3 Konstam, M.A., Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. Am J Cardiol 96 (2005), 867–871.
    • (2005) Am J Cardiol , vol.96 , pp. 867-871
    • Konstam, M.A.1
  • 4
    • 19344371011 scopus 로고    scopus 로고
    • Mechanisms of neurohormonal activation in chronic congestive heart failure: pathophysiology and therapeutic implications
    • 4 Davila, D.F., Nunez, T.J., Oderman, R., de Davila, C.A., Mechanisms of neurohormonal activation in chronic congestive heart failure: pathophysiology and therapeutic implications. Int J Cardiol 101 (2005), 343–346.
    • (2005) Int J Cardiol , vol.101 , pp. 343-346
    • Davila, D.F.1    Nunez, T.J.2    Oderman, R.3    de Davila, C.A.4
  • 5
    • 0041466344 scopus 로고    scopus 로고
    • Pre-discharge, but not admission levels of NT-proBNP predict adverse prognosis following acute left ventricular function
    • 5 O'Brien, R.J., Squire, I.B., Demme, B., Davies, J.E., Ng, L.L., Pre-discharge, but not admission levels of NT-proBNP predict adverse prognosis following acute left ventricular function. Eur J Heart Fail 5 (2003), 499–506.
    • (2003) Eur J Heart Fail , vol.5 , pp. 499-506
    • O'Brien, R.J.1    Squire, I.B.2    Demme, B.3    Davies, J.E.4    Ng, L.L.5
  • 6
    • 0037432301 scopus 로고    scopus 로고
    • Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial
    • 6 Anand, I.S., Fisher, L.D., Chiang, Y.-T., Latini, R., Masson, S., Maggioni, A.P., et al., Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial. Circulation 107 (2003), 1278–1283.
    • (2003) Circulation , vol.107 , pp. 1278-1283
    • Anand, I.S.1    Fisher, L.D.2    Chiang, Y.-T.3    Latini, R.4    Masson, S.5    Maggioni, A.P.6
  • 8
    • 2542492890 scopus 로고    scopus 로고
    • Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan Heart Failure Trial echocardiographic data
    • 8 Wong, M., Staszewsky, L., Latini, R., Barlera, S., Glazer, R., Aknay, N., et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan Heart Failure Trial echocardiographic data. J Am Coll Cardiol 43 (2004), 2022–2027.
    • (2004) J Am Coll Cardiol , vol.43 , pp. 2022-2027
    • Wong, M.1    Staszewsky, L.2    Latini, R.3    Barlera, S.4    Glazer, R.5    Aknay, N.6
  • 9
    • 84885842429 scopus 로고    scopus 로고
    • 2013 ACCF/AHA guideline for the management of heart failure: executive summary
    • e240–327
    • 9 Yancy, C.W., Jessup, M., Bozkhurt, B., Butler, J., Casey, D.E. Jr., Drazner, M.H., et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary. Circulation 128 (2013), 1810–1852 e240–327.
    • (2013) Circulation , vol.128 , pp. 1810-1852
    • Yancy, C.W.1    Jessup, M.2    Bozkhurt, B.3    Butler, J.4    Casey, D.E.5    Drazner, M.H.6
  • 10
    • 84892415130 scopus 로고    scopus 로고
    • Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification
    • 10 Bayes-Genis, A., de Antonio, M., Vila, J., Penafiel, J., Galan, A., Barallat, J., et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification. J Am Coll Cardiol 63 (2014), 158–166.
    • (2014) J Am Coll Cardiol , vol.63 , pp. 158-166
    • Bayes-Genis, A.1    de Antonio, M.2    Vila, J.3    Penafiel, J.4    Galan, A.5    Barallat, J.6
  • 11
    • 77951206972 scopus 로고    scopus 로고
    • Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure
    • 11 Christenson, R.H., Duh, S.-H., Wu, A.H., Smith, A., Abel, G., deFilippi, C.R., et al. Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clin Biochem 43 (2010), 683–690.
    • (2010) Clin Biochem , vol.43 , pp. 683-690
    • Christenson, R.H.1    Duh, S.-H.2    Wu, A.H.3    Smith, A.4    Abel, G.5    deFilippi, C.R.6
  • 12
    • 70349813786 scopus 로고    scopus 로고
    • Analytical and clinical evaluation of novel high-sensitivity assay for measurement of soluble ST2 in human plasma. The presage ST assay
    • 12 Dieplinger, B., Januzzi, J.L., Steinmair, M., Gabriel, C., Poelz, W., Haltmayer, M., et al. Analytical and clinical evaluation of novel high-sensitivity assay for measurement of soluble ST2 in human plasma. The presage ST assay. Clin Chim Acta 409 (2009), 33–40.
    • (2009) Clin Chim Acta , vol.409 , pp. 33-40
    • Dieplinger, B.1    Januzzi, J.L.2    Steinmair, M.3    Gabriel, C.4    Poelz, W.5    Haltmayer, M.6
  • 13
    • 84555204713 scopus 로고    scopus 로고
    • Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: Insights from the CARE-HF trial
    • 13 Lopez-Andres, N., Rossignot, P., Iraqi, W., Fay, R., Nuee, J., Ghio, S., et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: Insights from the CARE-HF trial. Eur J Heart Fail 14 (2012), 74–81.
    • (2012) Eur J Heart Fail , vol.14 , pp. 74-81
    • Lopez-Andres, N.1    Rossignot, P.2    Iraqi, W.3    Fay, R.4    Nuee, J.5    Ghio, S.6
  • 14
    • 1642502319 scopus 로고    scopus 로고
    • National kidney foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
    • 14 Levey, A.S., Coresh, J., Balk, E., Kausz, A.T., Levin, A., Steffes, M.W., et al. National kidney foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 139 (2003), 137–147.
    • (2003) Ann Intern Med , vol.139 , pp. 137-147
    • Levey, A.S.1    Coresh, J.2    Balk, E.3    Kausz, A.T.4    Levin, A.5    Steffes, M.W.6
  • 15
    • 41849140529 scopus 로고    scopus 로고
    • Concordance for survival time data: fixed and time-dependent covariates and possible ties in predictor and time. Technical report series no 80
    • Mayo Clinic Rochester, Minnesota
    • 15 Kremer, W.K., Concordance for survival time data: fixed and time-dependent covariates and possible ties in predictor and time. Technical report series no 80. 2007, Mayo Clinic, Rochester, Minnesota.
    • (2007)
    • Kremer, W.K.1
  • 16
    • 0003570192 scopus 로고    scopus 로고
    • Modeling survival data: extending the Cox model
    • Springer-Verlag New York
    • 16 Therneau, T.M., Grambsch, P.M., Modeling survival data: extending the Cox model. 2000, Springer-Verlag, New York.
    • (2000)
    • Therneau, T.M.1    Grambsch, P.M.2
  • 17
    • 38849091997 scopus 로고    scopus 로고
    • Evaluating the added predictive ability of new markers from area under the ROC curve to reclassification and beyond
    • 17 Pencina, M.J., d'Agostino, R.B. Sr., d'Agostino, R.B. Jr., Vasan, R.S., Evaluating the added predictive ability of new markers from area under the ROC curve to reclassification and beyond. Stat Med 27 (2008), 157–172.
    • (2008) Stat Med , vol.27 , pp. 157-172
    • Pencina, M.J.1    d'Agostino, R.B.2    d'Agostino, R.B.3    Vasan, R.S.4
  • 18
    • 79960815320 scopus 로고    scopus 로고
    • Evaluating the incremental value of new biomarkers with integrated discrimination improvement
    • 18 Kerr, K.F., McClelland, R.I., Brown, E.R., Lumley, T., Evaluating the incremental value of new biomarkers with integrated discrimination improvement. Am J Epidemiol 174 (2011), 364–374.
    • (2011) Am J Epidemiol , vol.174 , pp. 364-374
    • Kerr, K.F.1    McClelland, R.I.2    Brown, E.R.3    Lumley, T.4
  • 19
    • 0003474999 scopus 로고    scopus 로고
    • SAS/STAT user's guide, version 9 edition
    • SAS Institute Cary, North Carolina
    • 19 SAS Institute. SAS/STAT user's guide, version 9 edition. 2005, SAS Institute, Cary, North Carolina.
    • (2005)
  • 20
    • 84880072700 scopus 로고    scopus 로고
    • Biological variation of galectin-3 and soluble ST2 for chronic heart failure: Implication on the interpretation of test results
    • 20 Wu, A.H., Wians, F., Jaffe, A., Biological variation of galectin-3 and soluble ST2 for chronic heart failure: Implication on the interpretation of test results. Am Heart J 165 (2013), 995–999.
    • (2013) Am Heart J , vol.165 , pp. 995-999
    • Wu, A.H.1    Wians, F.2    Jaffe, A.3
  • 21
    • 78651387589 scopus 로고    scopus 로고
    • Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction
    • 21 De Boer, R.A., Lok, D.J., Jaarsma, T., van der Meer, P., Voors, A.A., Hillege, H.L., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43 (2011), 60–68.
    • (2011) Ann Med , vol.43 , pp. 60-68
    • De Boer, R.A.1    Lok, D.J.2    Jaarsma, T.3    van der Meer, P.4    Voors, A.A.5    Hillege, H.L.6
  • 22
    • 84877246724 scopus 로고    scopus 로고
    • Prognostic value of changes in galectin-3 levels over time in patients with heart failure (data from CORONA and COACH)
    • 22 van det Velde, A.R., Gullestad, L., Ueland, T., Aukrust, P., Guo, Y., Adourian, A., et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure (data from CORONA and COACH). Circ Heart Fail 6 (2013), 219–226.
    • (2013) Circ Heart Fail , vol.6 , pp. 219-226
    • van det Velde, A.R.1    Gullestad, L.2    Ueland, T.3    Aukrust, P.4    Guo, Y.5    Adourian, A.6
  • 23
    • 84892996801 scopus 로고    scopus 로고
    • Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin measurements in patients with chronic heart failure
    • 23 Gaggin, H.K., Szymonifka, J., Bhardwaj, A., Belcher, A., de Berardinis, B., Motiwala, S., et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin measurements in patients with chronic heart failure. J Am Coll Cardiol HF 2 (2014), 65–72.
    • (2014) J Am Coll Cardiol HF , vol.2 , pp. 65-72
    • Gaggin, H.K.1    Szymonifka, J.2    Bhardwaj, A.3    Belcher, A.4    de Berardinis, B.5    Motiwala, S.6
  • 24
    • 84866729958 scopus 로고    scopus 로고
    • Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community
    • 24 Ho, J.E., Liu, C., Lyass, A., Courchesne, P., Pencirna, M.J., Vasan, R.S., et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 60 (2012), 1249–1256.
    • (2012) J Am Coll Cardiol , vol.60 , pp. 1249-1256
    • Ho, J.E.1    Liu, C.2    Lyass, A.3    Courchesne, P.4    Pencirna, M.J.5    Vasan, R.S.6
  • 25
    • 77950230145 scopus 로고    scopus 로고
    • The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data form the GISSI–Heart Failure (GISSI-HF) trial
    • 25 Masson, S., Latini, R., Carbonieri, E., Moretti, L., Rossi, M.G., Iricugno, S., et al., GISSI-HF Investigators. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data form the GISSI–Heart Failure (GISSI-HF) trial. Eur J Heart Fail 12 (2010), 338–347.
    • (2010) Eur J Heart Fail , vol.12 , pp. 338-347
    • Masson, S.1    Latini, R.2    Carbonieri, E.3    Moretti, L.4    Rossi, M.G.5    Iricugno, S.6
  • 26
    • 84857111765 scopus 로고    scopus 로고
    • Serial measurements of mid-region pro-ANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure
    • 26 Miller, W.L., Hartman, K.A., Grill, D.E., Struck, J., Bergman, A., Jaffe, A.S., Serial measurements of mid-region pro-ANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure. Heart 98 (2012), 389–394.
    • (2012) Heart , vol.98 , pp. 389-394
    • Miller, W.L.1    Hartman, K.A.2    Grill, D.E.3    Struck, J.4    Bergman, A.5    Jaffe, A.S.6
  • 27
    • 84864592311 scopus 로고    scopus 로고
    • Cardiac microinjury measured by troponin T predicts collagen metabolism in adults aged ≥65 years with heart failure
    • 27 Kop, W.J., Gottdiener, J.S., deFilippi, C.R., Barasch, E., Seliger, S.L., Jenny, N.S., et al. Cardiac microinjury measured by troponin T predicts collagen metabolism in adults aged ≥65 years with heart failure. Circ Heart Fail 5 (2012), 406–413.
    • (2012) Circ Heart Fail , vol.5 , pp. 406-413
    • Kop, W.J.1    Gottdiener, J.S.2    deFilippi, C.R.3    Barasch, E.4    Seliger, S.L.5    Jenny, N.S.6
  • 28
    • 84999076186 scopus 로고    scopus 로고
    • Biomarkers in heart failure: the importance of inconvenient details. J Eur Soc Cardiol Heart Fail, In review.
    • 28 Miller WL, Jaffe AS. Biomarkers in heart failure: the importance of inconvenient details. J Eur Soc Cardiol Heart Fail, In review.
    • Miller, W.L.1    Jaffe, A.S.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.